Observational studyBreast cancer research and treatment2026
Real-world treatment patterns and outcomes in hormone receptor-positive, HER2-low metastatic breast cancer, 2018-2023: a retrospective, observational, US cohort study.
Observational study in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate real-world demographics, clinical characteristics, treatment patterns, and outcomes in US patients with ≥ 1 line of therapy (LOT) for hormone receptor-positive (HR+) HER2-low metastatic breast cancer (mBC).
methodsThis retrospective cohort study used a US-based electronic health record-derived de-identified database of patients with mBC diagnosed in 2018-2023. Patient demographics, clinical characteristics at date of mBC diagnosis, treatment patterns, and real-world overall survival (rwOS) and progression-free survival (rwPFS) were analyzed.
resultsOf 2662 patients, 49.4% had recurrent mBC. The median (Q1-Q3) number of LOTs was 2 (1-3). Endocrine therapy (ET) plus a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) was the most common first-line, second-line, and third-line therapy. In LOT1, 86.2% of patients received ET-containing regimens; consecutive use of ET-containing regimens in subsequent lines constituted 66.0%, 46.0%, 28.3%, and 19.3% of patients in LOT2-5, respectively. Of 830 patients who received chemotherapy, a median (Q1-Q3) of 1 (0-2) prior lines of ET-containing regimens were received. Median (95% CI) rwOS from mBC diagnosis was 42.4 (40.7, 45.0) months; 5-year survival was 36.9%. Median (95% CI) rwPFS decreased from 16.3 (15.2, 17.3) months in LOT1 to 9.1 (8.3, 10.0), 6.2 (5.6, 7.2), 5.3 (4.6, 6.1), and 3.8 (3.3, 4.9) months in LOT2-5, respectively.
conclusionsTreatment of HR+, HER2-low mBC was characterized by progressive endocrine exhaustion followed by later lines of chemotherapy, with outcomes worsening at each subsequent treatment line. Data highlight the need for new, effective treatment options in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.